Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary

Precigen

04/08/2026 22:02

Precigen, Inc. PGEN.OQ reported quarterly adjusted earnings of 5 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -9 cents.  The mean expectation of three analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents to -1 cents per share.
Revenue rose 6,322.7% to $54.98 million from a year ago; analysts expected $27.83 million. 
Precigen, Inc.'s reported EPS for the quarter was 5 cents​.
The company reported quarterly net income of $20.07 million.
Precigen, Inc. shares had risen by 16.0% this quarter and gained 58.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 14.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Precigen, Inc. is $12.50, about 47.1% above its last closing price of $6.61
This summary was machine generated from LSEG data August 4 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.01
0.05
Beat
Mar. 31 2026 
-0.03
-0.02
Beat
Dec. 31 2025 
-0.08
-0.07
Beat
Sep. 30 2025 
-0.09
-1.06
Missed